Theriva Sets 1-for-30 Reverse Split Effective December 1 to Regain NYSE American Compliance
TOVX is trading near its 52-week low of $0.12 (1.2% below the low) on light trading volume (0.4× avg).
Summary
Theriva will execute a 1-for-30 reverse split effective December 1, 2026, cutting outstanding shares from 45.9 million to about 1.53 million to satisfy NYSE American's per-share price rule — a compliance move coming days after a going-concern warning and a vote to expand authorized shares.
Key Events · Corporate Governance and Compliance · TOVX
-
1-for-30 Reverse Split Approved
The Board authorized the split on November 13, 2026; it takes effect at 11:59 p.m. ET on December 1, 2026, with split-adjusted trading beginning December 2 under ticker TOVX and new CUSIP 87164U607.
-
Share Count Cut to ~1.53 Million
Outstanding shares drop from 45,892,668 to approximately 1,529,756, and authorized shares fall proportionally from 350,000,000 to 11,666,666 — no net change in authorized headroom.
-
Listing Compliance Is the Stated Driver
Theriva says the split is being effected to meet the per-share price requirements of the NYSE American, its current listing exchange.
-
Going-Concern Backdrop
The Q3 10-Q filed November 12 reaffirmed substantial doubt about going concern with $8.5 million of cash funding operations only into Q1 2027, and stockholders approved raising authorized stock to 500,000,000 shares on November 18.
Analysis · TOVX · Life Sciences
Theriva is consolidating its shares 30-to-1 to lift the price above NYSE American's per-share listing threshold — the stock trades at $0.1186, essentially at its 52-week low of $0.12. The split itself creates no value: 45,892,668 shares become roughly 1,529,756, and authorized shares fall from 350,000,000 to 11,666,666, so the proportional reduction preserves the existing share-count headroom rather than adding any. What matters is the backdrop. Management reaffirmed substantial doubt about going concern in the Q3 10-Q filed November 12, with $8.5 million of cash funding operations only into Q1 2027, and stockholders just approved raising authorized stock to 500,000,000 shares on November 18 — a shelf of capacity that a reverse split now re-prices. A split executed from a position of listing weakness, days after a going-concern warning, usually precedes capital raising; the December 1 effective date is the next hard checkpoint.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TOVX was trading at $0.12 on NYSE in the Life Sciences sector, with a market capitalization of approximately $5.5M. The 52-week trading range was $0.12 to $0.49. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.